RU2680401C2 - Сульфонамиды в качестве модуляторов натриевых каналов - Google Patents
Сульфонамиды в качестве модуляторов натриевых каналов Download PDFInfo
- Publication number
- RU2680401C2 RU2680401C2 RU2016105511A RU2016105511A RU2680401C2 RU 2680401 C2 RU2680401 C2 RU 2680401C2 RU 2016105511 A RU2016105511 A RU 2016105511A RU 2016105511 A RU2016105511 A RU 2016105511A RU 2680401 C2 RU2680401 C2 RU 2680401C2
- Authority
- RU
- Russia
- Prior art keywords
- sulfamoylphenyl
- benzamide
- trifluoromethyl
- methoxyphenoxy
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361856146P | 2013-07-19 | 2013-07-19 | |
| US61/856,146 | 2013-07-19 | ||
| PCT/US2014/047265 WO2015010065A1 (en) | 2013-07-19 | 2014-07-18 | Sulfonamides as modulators of sodium channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016105511A RU2016105511A (ru) | 2017-08-24 |
| RU2016105511A3 RU2016105511A3 (enExample) | 2018-04-25 |
| RU2680401C2 true RU2680401C2 (ru) | 2019-02-21 |
Family
ID=51293175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016105511A RU2680401C2 (ru) | 2013-07-19 | 2014-07-18 | Сульфонамиды в качестве модуляторов натриевых каналов |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11203571B2 (enExample) |
| EP (1) | EP3022175B1 (enExample) |
| JP (1) | JP6337109B2 (enExample) |
| KR (1) | KR102215620B1 (enExample) |
| CN (1) | CN105683157B (enExample) |
| AP (1) | AP2016009023A0 (enExample) |
| AU (1) | AU2014290411B2 (enExample) |
| BR (1) | BR112016000825B1 (enExample) |
| CA (1) | CA2918365C (enExample) |
| CL (1) | CL2016000106A1 (enExample) |
| EC (1) | ECSP16005566A (enExample) |
| ES (1) | ES2654393T3 (enExample) |
| GE (1) | GEP20207102B (enExample) |
| HU (1) | HUE037876T2 (enExample) |
| IL (1) | IL243671B (enExample) |
| MX (1) | MX364155B (enExample) |
| NO (1) | NO2918662T3 (enExample) |
| PE (1) | PE20160548A1 (enExample) |
| PH (1) | PH12016500105A1 (enExample) |
| RU (1) | RU2680401C2 (enExample) |
| SG (1) | SG11201600383SA (enExample) |
| UA (1) | UA119147C2 (enExample) |
| WO (1) | WO2015010065A1 (enExample) |
| ZA (1) | ZA201600380B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| US9139529B2 (en) | 2013-01-31 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Substituted quinoxalines as sodium channel modulators |
| RU2680401C2 (ru) | 2013-07-19 | 2019-02-21 | Вертекс Фармасьютикалз Инкорпорейтед | Сульфонамиды в качестве модуляторов натриевых каналов |
| LT3080134T (lt) * | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| CA2944115A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Sulfonamide compounds as voltage gated sodium channel modulators |
| US11358977B2 (en) * | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| ES3008911T3 (en) | 2017-07-11 | 2025-03-25 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| CA3105748A1 (en) | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting nav1.8 |
| KR20210019581A (ko) * | 2018-07-09 | 2021-02-22 | 리버 인스티튜트, 아이엔씨 | Nav1.8을 억제하기 위한 피리딘 카르복스아미드 화합물 |
| MA54076A (fr) | 2018-11-02 | 2022-02-09 | Merck Sharp & Dohme | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 |
| EP3873468A4 (en) * | 2018-11-02 | 2022-10-26 | Merck Sharp & Dohme LLC | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
| MX2022015581A (es) | 2020-06-17 | 2023-01-24 | Merck Sharp & Dohme Llc | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. |
| CA3212699A1 (en) * | 2021-03-11 | 2022-09-15 | Latigo Biotherapeutics, Inc. | Methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use |
| MX2023013146A (es) | 2021-05-07 | 2023-11-28 | Merck Sharp & Dohme Llc | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8. |
| JP2024522292A (ja) | 2021-06-04 | 2024-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド |
| AU2022285758A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| CN117794919A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂 |
| BR112023025264A2 (pt) | 2021-06-04 | 2024-02-20 | Vertex Pharma | Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida |
| CN117858875A (zh) | 2021-06-04 | 2024-04-09 | 沃泰克斯药物股份有限公司 | 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂 |
| CN117813302A (zh) | 2021-06-04 | 2024-04-02 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂 |
| EP4511117A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| PE20251179A1 (es) | 2022-04-22 | 2025-04-23 | Vertex Pharma | Compuestos de heteroarilo para el tratamiento del dolor |
| JP2025513454A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| TW202408501A (zh) | 2022-04-22 | 2024-03-01 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| JP2025516005A (ja) | 2022-04-25 | 2025-05-23 | サイトワン セラピューティクス インコーポレイテッド | 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤 |
| CN116947713A (zh) * | 2022-04-25 | 2023-10-27 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
| KR20250069814A (ko) * | 2022-08-12 | 2025-05-20 | 광저우 페르미온 테크놀로지 씨오., 엘티디. | 전압 개폐 나트륨 채널 억제제로서의 화합물 |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| WO2024217344A1 (zh) * | 2023-04-19 | 2024-10-24 | 中国科学院上海药物研究所 | Nav1.8抑制剂及其制备方法和用途 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070238733A1 (en) * | 2006-04-11 | 2007-10-11 | Pramod Joshi | Compositions useful as inhibitors of voltage-gated sodium channels |
| RU2010118467A (ru) * | 2007-10-11 | 2011-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DK1303757T3 (da) | 2000-07-10 | 2007-02-05 | Vertex Pharma San Diego Llc | Ionkanal-assayfremgangsmåder |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| AR045238A1 (es) | 2003-08-08 | 2005-10-19 | Vertex Pharma | Compuestos utiles como inhibidores de canales ionicos regulados por voltaje |
| JP4056081B1 (ja) | 2004-07-23 | 2008-03-05 | ファイザー・インク | ピリジン誘導体 |
| TWI285415B (en) * | 2005-08-01 | 2007-08-11 | Advanced Semiconductor Eng | Package structure having recession portion on the surface thereof and method of making the same |
| AP2516A (en) | 2007-05-03 | 2012-11-26 | Pfizer Ltd | 2-Pyridine carboxamide derivatives as sodium channel modulators |
| WO2009049181A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| AU2008310660A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| EP2593434A1 (en) * | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| TWI520964B (zh) | 2011-02-02 | 2016-02-11 | 維泰克斯製藥公司 | 作為離子通道調節劑之吡咯并吡－螺環哌啶醯胺 |
| JP5940562B2 (ja) | 2011-02-18 | 2016-06-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド |
| EP2686325B1 (en) | 2011-03-14 | 2016-12-14 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| JP2014520151A (ja) * | 2011-06-20 | 2014-08-21 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 蠕虫感染を処置するためのヘテロ環式化合物 |
| US9365588B2 (en) | 2011-11-04 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Benzoxazines as modulators of ion channels |
| ES2631611T3 (es) | 2012-01-16 | 2017-09-01 | Vertex Pharmaceuticals Incorporated | Amidas de piperidina de Pirano-Espirociclico como moduladores de canales iónicos |
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| US9139529B2 (en) | 2013-01-31 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Substituted quinoxalines as sodium channel modulators |
| AR094668A1 (es) | 2013-01-31 | 2015-08-19 | Vertex Pharma | Amidas como moduladores de canales de sodio |
| RU2680401C2 (ru) | 2013-07-19 | 2019-02-21 | Вертекс Фармасьютикалз Инкорпорейтед | Сульфонамиды в качестве модуляторов натриевых каналов |
| LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| ES3008911T3 (en) | 2017-07-11 | 2025-03-25 | Vertex Pharma | Carboxamides as modulators of sodium channels |
-
2014
- 2014-07-18 RU RU2016105511A patent/RU2680401C2/ru active
- 2014-07-18 WO PCT/US2014/047265 patent/WO2015010065A1/en not_active Ceased
- 2014-07-18 MX MX2016000646A patent/MX364155B/es active IP Right Grant
- 2014-07-18 CN CN201480046803.9A patent/CN105683157B/zh active Active
- 2014-07-18 SG SG11201600383SA patent/SG11201600383SA/en unknown
- 2014-07-18 AU AU2014290411A patent/AU2014290411B2/en active Active
- 2014-07-18 BR BR112016000825-1A patent/BR112016000825B1/pt active IP Right Grant
- 2014-07-18 ES ES14748056.0T patent/ES2654393T3/es active Active
- 2014-07-18 CA CA2918365A patent/CA2918365C/en active Active
- 2014-07-18 EP EP14748056.0A patent/EP3022175B1/en active Active
- 2014-07-18 PE PE2016000077A patent/PE20160548A1/es unknown
- 2014-07-18 UA UAA201601499A patent/UA119147C2/uk unknown
- 2014-07-18 JP JP2016527141A patent/JP6337109B2/ja active Active
- 2014-07-18 US US14/906,089 patent/US11203571B2/en active Active
- 2014-07-18 GE GEAP201414060A patent/GEP20207102B/en unknown
- 2014-07-18 KR KR1020167004279A patent/KR102215620B1/ko not_active Expired - Fee Related
- 2014-07-18 HU HUE14748056A patent/HUE037876T2/hu unknown
- 2014-07-18 AP AP2016009023A patent/AP2016009023A0/en unknown
-
2015
- 2015-03-11 NO NO15158669A patent/NO2918662T3/no unknown
-
2016
- 2016-01-15 CL CL2016000106A patent/CL2016000106A1/es unknown
- 2016-01-18 PH PH12016500105A patent/PH12016500105A1/en unknown
- 2016-01-18 ZA ZA2016/00380A patent/ZA201600380B/en unknown
- 2016-01-19 IL IL243671A patent/IL243671B/en active IP Right Grant
- 2016-02-11 EC ECIEPI20165566A patent/ECSP16005566A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070238733A1 (en) * | 2006-04-11 | 2007-10-11 | Pramod Joshi | Compositions useful as inhibitors of voltage-gated sodium channels |
| RU2010118467A (ru) * | 2007-10-11 | 2011-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов |
Non-Patent Citations (1)
| Title |
|---|
| NIELSEN F E ET AL. Bioorganic & Medicinal Chemistry Letters, vol.14, no. 23, 06.12.2004, pp. 5727-5730. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2680401C2 (ru) | Сульфонамиды в качестве модуляторов натриевых каналов | |
| RU2658920C2 (ru) | Амиды в качестве модуляторов натриевых каналов | |
| RU2683788C2 (ru) | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов | |
| JP6389194B2 (ja) | ナトリウムチャネルの調節剤としてのピリドンアミド | |
| JP2019055974A (ja) | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ | |
| RU2808424C2 (ru) | Пиридонамиды в качестве модуляторов натриевых каналов | |
| HK1223604B (en) | Sulfonamides as modulators of sodium channels | |
| HK1217692B (en) | Amides as modulators of sodium channels | |
| HK1217691B (en) | Quinoline and quinazoline amides as modulators of sodium channels |